Together, Little Place Labs and Loft Orbital are paving the way for a new era of rapid-response capabilities in space. Photo courtesy of Little Place Labs

A Houston space startup has announced a new partnership that will “push the boundaries of real-time data processing and insight delivery.”

Little Place Labs is collaborating with San Francisco-based Loft Orbital to pair its low-latency operations, using its space infrastructure with LittlePlace Labs’ cutting-edge analytics. This will enhance maritime domain awareness under a US Air Force Phase 2 STTR by deploying Little Place Labs software to Loft’s YAM-6 satellite as a virtual mission.

“Our on-orbit data processing solutions, paired with Loft’s satellite platform, allow us to derive and deliver insights in near real-time for time-sensitive situations,” Little Place Labs Co-founder and CEO Bosco Lai says in a news release. “These insights are critical to commercial and national security stakeholders, including those in the US government. This collaboration highlights the new space age, where companies like Little Place Labs and Loft come together, integrating our solutions into powerful capabilities.”

Loft plans to deploy Little Place Labs’ applications to its constellation of satellites. Each satellite node will be equipped with a sensing resource like visible and infrared images, and configurable software-defined radios. The satellite nodes make up Loft’s space infrastructure, which will include onboard edge compute and connectivity resources. The infrastructure will be used to build and complete complex missions. The low-latency maritime domain awareness is an example of the complex challenges that won’t involve deployment of new hardware. This aligns with both companies goals to address real-time data solutions and rapid responses in space.

"We are proud to support customers like Little Place Labs in pushing the limits of what’s possible with low latency applications and onboard edge compute,” Mitchell Scher, director of business development at Loft, adds. “While we’re providing the infrastructure to support these kinds of low-latency operations, it is only as useful as the applications our customers deploy and the operational value they produce for their end users.”

Little Place Labs will be working with another military organization, as they were recently selected by AFWERX for a STTR Phase II contract in the amount of $1.8 million dollars. The focus will be “revolutionizing space- based ISR through decentralized systems,” per a news release. This will be done in-orbit ML computing for near-real-time intelligence to address challenges in the Department of the Air Force.

Another recent collaboration sees their Orbitfy software suite on LEOcloud’s Space Edge infrastructure as a Service (IaaS). This will help facilitate “scalable real-time data processing and analysis directly on spacecraft, significantly reducing downlink costs and enabling faster mission-critical insight,” according to a news release. The Orbitfy Software suite combines data preprocessing capabilities with low-SWaP machine learning applications that is designed for deployment directly on space infrastructures and satellites.

Little Place Labs is also using its satellite real-time solutions to help address wildfires. They were one of four companies part of the completion of the first round of the XPRIZE Autonomous Wildfire Challenge by the coalition Fire Foresight.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.